Histiocyte-rich rhabdomyoblastic tumor: a clinicopathological and molecular genetic analysis.
10.3760/cma.j.cn112151-20210829-00624
- Author:
Zhi Jie YOU
1
;
Ling Ying KONG
2
;
Chen WANG
3
;
Xiao Yan CHEN
3
;
Xin CHEN
3
;
Xun Bin YU
3
Author Information
1. Department of Pathology, Fujian Provincial Hospital South Branch, Fuzhou 350028, China.
2. Department of Pathology, Fujian University of Traditional Chinese Medicine Affiliated People's Hospital, Fuzhou 350004, China.
3. Department of Pathology, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350001, China.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor/analysis*;
Diagnosis, Differential;
Histiocytes/pathology*;
Humans;
Molecular Biology;
Muscle Neoplasms/pathology*;
Prognosis
- From:
Chinese Journal of Pathology
2022;51(5):425-430
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinicopathologic and molecular genetic characteristics, diagnosis, differential diagnosis, treatment and prognosis of histiocyte-rich rhabdomyoblastic tumor (HRRMT). Methods: The clinical data of two cases of HRRMT diagnosed in Fujian Provincial Hospital and Fujian University of Traditional Chinese Medicine Affiliated People's Hospital from 2020 to 2021 were collected. Histopathology and immunohistochemical (IHC) staining were used to assess morphological changes; the genetic changes were analyzed with next-generation sequencing. The relevant literature was reviewed. Results: Both cases showed well-defined solid nodules and soft masses. Microscopically, the tumors had a fibrous pseudocapsule with lymphocytic aggregation, and locally invaded the surrounding skeletal muscle tissue, and the tumor cells were fusiform to epithelioid with an intensive foamy histiocytic infiltrate. No necrosis or mitosis was observed. Immunophenotyping showed the tumor cells were positive for desmin, either one or both skeletal muscle markers (myogenin or MyoD1), and negative for h-caldesmon, ALK and SMA. The Ki-67 index was<5%. Using next-generation sequencing, one case was found to harbour KRAS (G12D) and MSH3 (Q470*) mutations. Conclusions: HRRMT is a newly described skeletal muscle tumor with uncertain malignant potential. Its diagnosis and differential diagnosis depend on morphologic and IHC staining. No specific molecular genetics changes have been identified so far.
